Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world outcomes of Axicabtagene injection in relapsed or refractory non-Hodgkin's lymphoma
ChiCTR2100047990Phase 4Recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Jun 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of axicabtagene ciloleucel in non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoints: overall survival, best objective response rate and 4 more. Started Jun 2021; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2100047990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047990.